Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Regulatory Routine +

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI(TM) (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 08:00 BHC · 7.16 BAUSCH HEALTH COMPANIES INC.
Executive Summary
  • Bausch Health, Canada Inc. signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) to secure public drug plan coverage for PrOKEDI (risperidone extended-release injectable suspension) for schizophrenia.
  • The LOI follows positive Phase 3 PRISMA-3 trial data showing significant symptom improvement versus placebo and a 12-month extension confirming sustained disease stability.
  • Next steps involve finalizing Product Listing Agreements with federal, provincial, and territorial public drug plans to enable patient access.
  • This is a standard commercial/regulatory milestone for the Canadian pharmaceutical portfolio, not a transformative corporate event.
Material Impact
  • The PrOKEDI LOI is a positive commercial milestone for the Canadian portfolio but does not alter the company's fundamental debt profile, pipeline trajectory, or tariff exposure.
  • The stock had already declined -6.5% into the print, indicating that skepticism regarding the RED-C failure, tariff headwinds, and leverage was already discounted.
  • The news is Routine - Positive. It provides incremental commercial visibility but lacks the scale to re-rate the business or meaningfully impact the ~$2.65B market cap.
BHC · Price
Company Overview
  • Bausch Health is a diversified global pharmaceutical and healthcare company with segments in gastroenterology (Salix), aesthetics (Solta Medical), eye health (Bausch + Lomb), international pharma, and diversified products.
  • Strategic focus includes debt reduction, pipeline development (Larsucosterol for alcohol-associated hepatitis), and geographic expansion in China via the Shibo acquisition.
  • The company is navigating a complex transition from legacy litigation settlements to a leaner, debt-focused operating model while preparing for Xifaxan loss-of-exclusivity in 2028.
Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

Jul 01, 2026 · 16:15

Michael Goettler Resigns from Bausch Health's Board of Directors

Management May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations May 19, 2026 · 16:15

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

Regulatory May 12, 2026 · 16:15

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Other Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other